All programmes are at candidate-selection / preclinical stage. The profiles below summarise the design intent recorded in the company's development plan; they are not clinical claims.
A weekly long-acting peptide programme. In non-clinical profiling at 10–30 nM it shows glucose-lowering and weight-control activity comparable to semaglutide, with faster onset of glucose reduction than semaglutide and tirzepatide. Chemical class and target are disclosed under a confidentiality agreement.
A first-in-class, regeneration-oriented peptide programme designed for weekly dosing. It targets glucose stabilisation in mild diabetes and, with regeneration as the goal, addresses early-onset and paediatric diabetes where a durable solution matters most. Chemical class, target and structural detail are disclosed under a confidentiality agreement.
A multi-target peptide combining several metabolic receptor activities in one molecule, developed as a monthly-format glucose-lowering and weight-management agent.
A long-acting fusion protein that mimics an endogenous hormone co-secreted with insulin by pancreatic β-cells. Acting through complementary mechanisms alongside insulin signalling, it supports glycaemic control and shows potential in weight management. Composition and target are disclosed under a confidentiality agreement.
A dual-action long-acting fusion protein for NASH, type 2 diabetes, obesity and metabolic syndrome, combining systemic metabolic regulation with gut-barrier repair and anti-inflammatory activity — two mechanisms in one molecule. Domain composition and target are disclosed under a confidentiality agreement.